hepalink announces the appointment of healthcare senior executive mr. frank sun as executive director and vice chairman of the board
shenzhen, china--(business wire)—shenzhen hepalink pharmaceutical group co., ltd. (szse: 002399), a china-based global pharmaceutical company targeting high-mortality diseases with significant unmet medical needs, announced the appointment of mr. frank sun as executive director and the election of mr. sun as the vice chairman of the board. mr. sun will work with the board on strategy design, enhancement and implementation, and lead the efforts in strategic investment, capital markets, and the development of hepalink’s innovative businesses globally.
mr. sun graduated with distinction and received his mba from nyu stern school of business. he has a master’s degree in pharmacology from columbia university. mr. sun is a director of the china healthcare investment 50 forum (h50).
this article is reproduced from: business wire